Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon
Thumbnail

Court blocks aspects of surprise billing rule

Federal Judge Jeremy D. Kernodle said the interim final rule conflicts with the unambiguous terms of the No Surprises Act.

Thumbnail

HHS allocating $560M in payments to healthcare providers impacted by COVID-19 pandemic

Nearly $19 billion will have been distributed from the Provider Relief Fund and the American Rescue Plan Rural provider funding since November 2021.

Thumbnail

Quality care for geriatric patients lacking in emergency departments

Most EDs do not provide the level of care recommended by Geriatric Emergency Department guidelines.

Major pharmacy group criticizes FTC decision on PBMs

FTC failed to reach a consensus on a study looking into PBM practices.

M&A mergers and acquisitions business deal

M&A activity was down in 2021, but 'mega-mergers' spiked

Last year saw the largest percentage of mega transactions over the past six years at 16.3%, nearly double that of 2020.

AMA releases new toolkit with 5 steps to achieve racial, health equity

The "Racial and Health Equity: Concrete STEPS for Health Systems toolkit is the latest addition to a collection of more than 70 other toolkits that cover transformative medical practice solutions.

Thumbnail

Health-tech companies back new legislation introduced to modernize ‘outdated’ health privacy laws

Teladoc Health, IBM, Epic and others all support the bipartisan Health Data Use and Privacy Commission Act.

With patient safety slipping, CDC and CMS turn focus to more resilient approaches

COVID-19 has led to a quick and steep decline in patient safety across the entire American healthcare system.

Displaying 649 - 656 of 2773

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup